Old Bladder Drug Shows Promise Against Devastating Mitochondrial Diseases

A common medication, typically prescribed for bladder incontinence, is emerging as a potential new weapon against debilitating mitochondrial diseases. Researchers have discovered that oxybutynin can significantly improve muscle stem cell function in the presence of mitochondrial dysfunction, offering a glimmer of hope for patients with these genetic illnesses.

Key Takeaways

• Oxybutynin, an established drug for bladder issues, shows efficacy in combating mitochondrial dysfunction.
• The drug enhances cellular glycolysis, providing an alternative energy source for cells when mitochondria are impaired.
• Studies on mouse and human muscle stem cells demonstrate improved growth and energy levels with oxybutynin treatment.
• Repurposing this existing drug could expedite the development of new therapies for mitochondrial diseases.

A Surprising New Role for an Old Drug

Mitochondrial diseases, affecting approximately one in every 5,000 people, often manifest in childhood with severe muscle weakness, neurological decline, and heart problems. Currently, there are no cures and very limited treatment options. The Cornell University research team, led by Joeva Barrow, explored a novel approach by screening thousands of small molecules for their potential to treat mitochondrial disease directly in muscle stem cells.

Rewiring Cellular Energy Pathways

Oxybutynin emerged as a promising candidate. Instead of repairing the damaged mitochondria, the drug appears to reroute cellular energy production. It enhances glycolysis, a rapid process of breaking down glucose, which provides a crucial energy backup for cells when their mitochondria are unable to produce sufficient ATP. This metabolic shift allows muscle stem cells, which are vital for muscle repair and growth, to overcome the energy deficit caused by mitochondrial dysfunction.

Promising Results in Lab Studies

Experiments conducted on both mouse and human muscle stem cells treated with oxybutynin showed remarkable improvements. The treated cells exhibited increased multiplication, enhanced formation of muscle fibers, and sustained higher energy levels compared to untreated cells. This suggests that oxybutynin can help diseased muscle cells find alternative ways to survive and function.

Towards Clinical Application

Further research is underway, with collaborations extending to the Children's Hospital of Philadelphia, where oxybutynin is being tested on cells from children with mitochondrial diseases. While human trials specifically for mitochondrial disease have not yet occurred, the FDA approval of oxybutynin for other conditions means that if further studies confirm its benefits, it could potentially bypass years of costly development and reach patients more quickly. This discovery offers a significant ray of hope for families affected by these devastating genetic disorders.

Sources

• Decades-old drug deployed in fight against mitochondrial diseases, Cornell Chronicle.